G Belcher
Overview
Explore the profile of G Belcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fields T, Patterson M, Bremova-Ertl T, Belcher G, Billington I, Churchill G, et al.
Trials
. 2021 Jan;
22(1):84.
PMID: 33482890
Background: The lack of approved treatments for the majority of rare diseases is reflective of the unique challenges of orphan drug development. Novel methodologies, including new functionally relevant endpoints, are...
2.
Belcher G, Schernthaner G
Diabet Med
. 2005 Jul;
22(8):973-9.
PMID: 16026360
Aims: Patients with Type 2 diabetes are at increased risk of liver damage. Therefore, it is of particular importance to investigate the hepatic effects of drugs used to treat such...
3.
Belcher G, Lambert C, Goh K, Edwards G, Valbuena M
Int J Clin Pract
. 2004 Nov;
58(9):833-7.
PMID: 15529516
Cardiovascular mortality and morbidity are increased in patients with type 2 diabetes. However, there are few data from clinical trials comparing cardiovascular effects of alternative oral anti-diabetic agents. Major cardiovascular...
4.
Erdmann E, George M, Voet B, Belcher G, Kolb D, Hiemstra S, et al.
J Renin Angiotensin Aldosterone Syst
. 2002 Apr;
1 Suppl 1:31-6.
PMID: 11967795
The management of congestive heart failure (CHF) continues to represent a major therapeutic challenge. The primary goal of any treatment is the improvement of symptoms with a reduction in CHF...
5.
Hanefeld M, Belcher G
Int J Clin Pract Suppl
. 2001 Oct;
(121):27-31.
PMID: 11594241
The safety profile of pioglitazone has been evaluated in trials including over 5,400 subjects, of whom over 3,500 received active treatment resulting in over 2,500 patient-years of exposure. Since its...
6.
Watson H, Belcher G, Horrocks M
Br J Surg
. 2001 Oct;
88(10):1376-81.
PMID: 11578295
Background: Graft patency is usually the primary endpoint in studies of peripheral arterial bypass surgery, but gives only a limited indication of clinical outcome. The aim of this study was...
7.
Watson H, Skene A, Belcher G
Br J Clin Pharmacol
. 2000 May;
49(5):479-83.
PMID: 10792206
Aims: To investigate the characteristics of published trials in order to establish the origin of the differing results obtained in trials of platelet inhibitors after peripheral bypass procedures. Methods: Analysis...
8.
Watson H, Belcher G, Horrocks M
Br J Surg
. 1999 Aug;
86(8):981-91.
PMID: 10460632
Background: A review was conducted of published clinical trials of adjuvant medical therapy in infrainguinal bypass procedures to evaluate the strength of the evidence for the use of various agents....
9.
Watson H, Robb R, Belcher G, Belch J
J Rheumatol
. 1999 Aug;
26(8):1734-7.
PMID: 10451070
Objective: Patients with systemic sclerosis (SSc) were assessed for 12 months to quantify the seasonal variation in Raynaud's phenomenon (RP) in patients with an underlying connective tissue disease. Methods: Eighteen...
10.
Schmalzried T, Szuszczewicz E, Northfield M, Akizuki K, Frankel R, Belcher G, et al.
J Bone Joint Surg Am
. 1998 Feb;
80(1):54-9.
PMID: 9469309
Accumulating data suggest that the amount of use, and not simply the duration in situ, influences the wear and survival of total joint replacements. An electronic, digital pedometer was used...